Literature DB >> 12078793

Platelet activation, aggregation, and life span in calves implanted with axial flow ventricular assist devices.

Trevor A Snyder1, Mary J Watach, Kenneth N Litwak, William R Wagner.   

Abstract

BACKGROUND: A variety of rotary blood pumps are under development worldwide to serve as chronic ventricular assist devices (VADs). Historically VADs have been associated with thrombotic and thromboembolic complications, yet the ability to evaluate the thrombotic process in preclinical device testing has been limited.
METHODS: We have developed and applied flow cytometric assays for activated platelets, platelet microaggregates, and platelet life span and consumption to calves implanted with an axial flow VAD and calves undergoing a sham surgical procedure.
RESULTS: Surgical sham calves had significant increases in circulating activated platelets (p < 0.05) that resolved within 17 days, and no increases in circulating platelet microaggregates. Calves with uneventful VAD implant periods had early transient elevations in platelet microaggregates and prolonged elevations in activated platelets that did not recover to preoperative values during the study. Daily platelet consumption in VAD implanted calves was increased by 20% +/- 3%. Calves with thrombotic deposition within the VAD and elevated thromboembolism observed at autopsy experienced increases in circulating activated platelets and microaggregates at the end of the implant period when VAD flow decreased.
CONCLUSIONS: This study demonstrates the ability of flow cytometry-based platelet assays to differentiate VAD implant operations from VAD support, and suggests differences that exist between uneventful VAD support and support with complications. These techniques should have value in evaluating other cardiovascular devices undergoing preclinical testing and provide insight into the temporal impact of these devices on the hemostatic system.

Entities:  

Mesh:

Year:  2002        PMID: 12078793     DOI: 10.1016/s0003-4975(02)03549-x

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  14 in total

1.  Flow cytometric assays for quantifying activated ovine platelets.

Authors:  Carl A Johnson; Trevor A Snyder; Joshua R Woolley; William R Wagner
Journal:  Artif Organs       Date:  2007-11-14       Impact factor: 3.094

2.  Biocompatibility Assessment of the CentriMag-Novalung Adult ECMO Circuit in a Model of Acute Pulmonary Hypertension.

Authors:  Venkat Shankarraman; Ergin Kocyildirim; Salim E Olia; Marina V Kameneva; Ryan J Dzadony; Timothy M Maul; Marc A Simon; Hunter C Champion; William R Wagner; Christian A Bermudez
Journal:  ASAIO J       Date:  2014 Jul-Aug       Impact factor: 2.872

3.  Biocompatibility assessment of the first generation PediaFlow pediatric ventricular assist device.

Authors:  Carl A Johnson; Stijn Vandenberghe; Amanda R Daly; Joshua R Woolley; Shaun T Snyder; Josiah E Verkaik; Sang-Ho Ye; Harvey S Borovetz; James F Antaki; Peter D Wearden; Marina V Kameneva; William R Wagner
Journal:  Artif Organs       Date:  2011-01       Impact factor: 3.094

4.  Platelet activation after implantation of the Levitronix PediVAS in the ovine model.

Authors:  Carl A Johnson; Venkat Shankarraman; Peter D Wearden; Ergin Kocyildirim; Timothy M Maul; John D Marks; J Scott Richardson; Barry N Gellman; Harvey S Borovetz; Kurt A Dasse; William R Wagner
Journal:  ASAIO J       Date:  2011 Nov-Dec       Impact factor: 2.872

5.  Preoperative liver dysfunction influences blood product administration and alterations in circulating haemostatic markers following ventricular assist device implantation.

Authors:  Joshua R Woolley; Robert L Kormos; Jeffrey J Teuteberg; Christian A Bermudez; Jay K Bhama; Kathleen L Lockard; Nicole M Kunz; William R Wagner
Journal:  Eur J Cardiothorac Surg       Date:  2014-05-07       Impact factor: 4.191

6.  Blood biocompatibility assessment of an intravenous gas exchange device.

Authors:  Trevor A Snyder; Heide J Eash; Kenneth N Litwak; Brian J Frankowski; Brack G Hattler; William J Federspiel; William R Wagner
Journal:  Artif Organs       Date:  2006-09       Impact factor: 3.094

7.  Thromboresistance comparison of the HeartMate II ventricular assist device with the device thrombogenicity emulation- optimized HeartAssist 5 VAD.

Authors:  Wei-Che Chiu; Gaurav Girdhar; Michalis Xenos; Yared Alemu; Jõao S Soares; Shmuel Einav; Marvin Slepian; Danny Bluestein
Journal:  J Biomech Eng       Date:  2014-02       Impact factor: 2.097

8.  Scaling the Low-Shear Pulsatile TORVAD for Pediatric Heart Failure.

Authors:  Jeffrey R Gohean; Erik R Larson; Brian H Hsi; Mark Kurusz; Richard W Smalling; Raul G Longoria
Journal:  ASAIO J       Date:  2017 Mar/Apr       Impact factor: 2.872

9.  Close antiplatelet therapy monitoring and adjustment based upon thrombelastography may reduce late-onset bleeding in HeartMate II recipients.

Authors:  Ashkan Karimi; Thomas M Beaver; Philip J Hess; Tomas D Martin; Edward D Staples; Richard S Schofield; James A Hill; Juan M Aranda; Charles T Klodell
Journal:  Interact Cardiovasc Thorac Surg       Date:  2014-01-12

10.  Surface modification of a titanium alloy with a phospholipid polymer prepared by a plasma-induced grafting technique to improve surface thromboresistance.

Authors:  Sang Ho Ye; Carl A Johnson; Joshua R Woolley; Heung-Il Oh; Lara J Gamble; Kazuhiko Ishihara; William R Wagner
Journal:  Colloids Surf B Biointerfaces       Date:  2009-07-07       Impact factor: 5.268

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.